

Return on Innovation



Global health R&D delivers for Maryland



US government (USG) investment in global health R&D has delivered

\$2.5 billion

to Maryland research institutions*

30,700+ new jobs

for Maryland†

Maryland's top global health R&D institutions by USG funding*

ORGANIZATION	FUNDING
National Institutes of Health (self-funding & other agency transfers)	\$1.6 billion
Johns Hopkins University	\$222.5 million
The Henry M. Jackson Foundation for the Advancement of Military Medicine	\$221.9 million
U.S. Army Fort Detrick	\$151.8 million
University of Maryland, Baltimore	\$108.6 million
International Partnership for Microbicides	\$44.7 million
Leidos Biomedical Research	\$39.6 million

Neglected diseases in Maryland‡

HIV diagnoses	13,396
Tuberculosis cases	1,941
Malaria cases	804
West Nile cases	177
Zika cases	142

Maryland industry in global health R&D

AstraZeneca: Frederick, Gaithersburg
Celgene: Odenton
GSK: Rockville
Leidos Biomedical Research: Bethesda, Fort Detrick, Frederick
Sanofi: Bethesda


Global health R&D at work in the Old Line State



Maryland GovPics/JayBaker

The University of Maryland has developed a vaccine, Vaxchora™, to protect US adults traveling to cholera-affected areas. Vaxchora is the only cholera vaccine available in the United States, and the only single-dose vaccine for cholera licensed anywhere. Acquired through contaminated food or water, cholera can kill in less than 24 hours if left untreated. Widespread in 69 countries, this highly contagious disease impacts millions of people worldwide each year.

Maryland's top areas of global health R&D by USG funding*



GLOBAL HEALTH R&D IS A SMART INVESTMENT FOR THE UNITED STATES‡



89¢ of every dollar

the USG invests in global health R&D stays within the United States, **supporting the domestic economy.**

USG investment in global health R&D between 2007 and 2015 **generated an estimated:**

200K new US jobs

\$33 BILLION in US economic growth.

*Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See www.ghtcoalition.org for full methodology.

†Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See www.ghtcoalition.org for additional details.

‡Centers for Disease Control and Prevention: HIV diagnoses 2008–2016, Tuberculosis cases 2008–2016, Malaria cases 2008–2014, West Nile virus disease cases 2008–2016, Zika virus disease cases 2015–2017.

§Source: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. 2017.

¶NTD: neglected tropical disease. NTDs include Buruli ulcer, Dengue, Helminths, Kinetoplastids, Leprosy, Trachoma, and Leptospirosis.